$ZSAN in Bullish Crossover
ZSAN President and chief executive officer, Steven Lo, will present a company overview at the BTIG Biotechnology Conference 2020 on Tuesday, August 11, 2020 at 3:00 pm ET. (Possible Catalyst this week) Released earnings last week.
Pt between $2.40 to $3.13
Qtrypta is Zosano's transdermal microneedle product candidate for the acute treatment of migraine. In March, the U.S. Food and Drug Administration (FDA) accepted a New Drug Application for Qtrypta and granted a Prescription Drug User Fee Act (PDUFA) goal date of October 20, 2020.
Pt between $2.40 to $3.13
Qtrypta is Zosano's transdermal microneedle product candidate for the acute treatment of migraine. In March, the U.S. Food and Drug Administration (FDA) accepted a New Drug Application for Qtrypta and granted a Prescription Drug User Fee Act (PDUFA) goal date of October 20, 2020.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.